[Asia Economy Reporter Eunmo Koo] ST Pharm announced on the 16th that it has signed a fee agreement for investment support and facility usage for oligo production equipment with a Europe-based global pharmaceutical company. The contract is conditional, with a confirmed contract amount of 56.5564 billion KRW and a conditional contract amount of 9.18 billion KRW. The contract amount represents 70.48% of last year's consolidated sales, and the contract period is until December 31, 2030.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing